126 related articles for article (PubMed ID: 23612992)
1. Candidate microbicides and their mechanisms of action.
Herrera C; Shattock RJ
Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
[TBL] [Abstract][Full Text] [Related]
2. Microbicides for multidrug-resistant and multitropic HIV-1.
D'Cruz OJ; Uckun FM
Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
Menéndez-Arias L
Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
[TBL] [Abstract][Full Text] [Related]
5. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1.
Pirrone V; Wigdahl B; Krebs FC
Antiviral Res; 2011 Jun; 90(3):168-82. PubMed ID: 21439325
[TBL] [Abstract][Full Text] [Related]
6. Microbicides for prevention of HIV infection: clinical efficacy trials.
Abdool Karim SS; Baxter C
Curr Top Microbiol Immunol; 2014; 383():97-115. PubMed ID: 23695725
[TBL] [Abstract][Full Text] [Related]
7. Anti-HIV drug development--an overview.
Pereira CF; Paridaen JT
Curr Pharm Des; 2004; 10(32):4005-37. PubMed ID: 15579085
[TBL] [Abstract][Full Text] [Related]
8. Potential use of protease inhibitors as vaginal and colorectal microbicides.
Herrera C; Shattock RJ
Curr HIV Res; 2012 Jan; 10(1):42-52. PubMed ID: 22264045
[TBL] [Abstract][Full Text] [Related]
9. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
Murray JM
J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
[No Abstract] [Full Text] [Related]
10. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
Sierra-Aragón S; Walter H
Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
[TBL] [Abstract][Full Text] [Related]
11. Microbicide dosage forms.
Rohan LC; Devlin B; Yang H
Curr Top Microbiol Immunol; 2014; 383():27-54. PubMed ID: 24220751
[TBL] [Abstract][Full Text] [Related]
12. Clinical safety and pharmacology trial.
Mauck C; Thurman A; Schwartz J
Curr Top Microbiol Immunol; 2014; 383():79-95. PubMed ID: 24173586
[TBL] [Abstract][Full Text] [Related]
13. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
14. Sulfated K5 Escherichia coli polysaccharide derivatives inhibit human immunodeficiency type-1 (HIV-1) infection: candidate microbicides to prevent sexual HIV transmission.
Pacciarini F; Ghezzi S; Pinna D; Cima S; Zoppetti G; Oreste P; Poli G; Vicenzi E
New Microbiol; 2004 Apr; 27(2 Suppl 1):5-9. PubMed ID: 15646059
[TBL] [Abstract][Full Text] [Related]
15. Electrospun fibers for vaginal anti-HIV drug delivery.
Blakney AK; Ball C; Krogstad EA; Woodrow KA
Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
[TBL] [Abstract][Full Text] [Related]
16. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
D'Cruz OJ; Uckun FM
J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
18. Preclinical safety evaluation.
Holt JD; Nuttall JP
Curr Top Microbiol Immunol; 2014; 383():55-78. PubMed ID: 23612993
[TBL] [Abstract][Full Text] [Related]
19. Developing regulatory strategy for microbicides.
Nardi R; Arterburn L; Carlton L
Curr Top Microbiol Immunol; 2014; 383():137-52. PubMed ID: 24126799
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of the human immunodeficiency virus: current and future targets for intervention.
Krogstad P
Semin Pediatr Infect Dis; 2003 Oct; 14(4):258-68. PubMed ID: 14724791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
